10:57 AM EST, 12/27/2024 (MT Newswires) -- Shares of Outlook Therapeutics ( OTLK ) were up Friday after the biopharmaceutical company reported a loss of $4.06 per share for fiscal 2024, narrowing from a loss of $4.72 a year earlier.

Six analysts surveyed by FactSet estimated a loss of $4.91 per share.

The company didn't report any revenue for the year ended Sept. 30.

Price: 1.96, Change: +0.26, Percent Change: +15.35